The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.


Journal Article (Review)

Results from clinical trials of glycoprotein IIb/IIIa(GPIIb/IIIa) inhibitors during the past decade have established their current role in the treatment of non-ST-segment elevation acute coronary syndrome and in percutaneous coronary interventions. However, there are still unanswered questions on optimal use of GPIIb/IIIa inhibitors. Moreover, as new concomitant or alternative medications become available, the role of GPIIb/IIIa inhibitors must be reconsidered. This review discusses, in the light of clinical trials recently presented, what we know, what we are learning, and what we still need to learn.

Full Text

Duke Authors

Cited Authors

  • Tricoci, P; Peterson, ED

Published Date

  • October 2006

Published In

Volume / Issue

  • 19 / 5

Start / End Page

  • 449 - 455

PubMed ID

  • 17020570

Pubmed Central ID

  • 17020570

International Standard Serial Number (ISSN)

  • 0896-4327

Digital Object Identifier (DOI)

  • 10.1111/j.1540-8183.2006.00182.x


  • eng

Conference Location

  • United States